Out-licensing opportunities
MolMed’s business strategy strongly relies on establishing strategic alliances with major biotech and pharmaceutical companies, in order to foster the development of its leading products through co-development, co-marketing or out-licensing partnerships.
MolMed intends to out-license some of its leading products for selected indications and territories:
-
NGR-hTNF vascular targeting agent: MolMed is seeking a co-development or out-licensing partnership to take NGR-hTNF through its full clinical programme to product commercialisation. MolMed is particularly interested in collaborations with major pharmaceutical or medical biotech companies seeking to strengthen their existing oncology portfolio.
-
AIDS gene therapy: MolMed makes available for out-licensing a novel therapeutic gene, Chim3. Chim3 is a mutant of the Vif gene conferring resistance to HIV infection (patent pub. WO/2006/111866 filed in Europe, U.S., Japan, Australia, Canada, China, India, Singapore and South Korea). Chim3 belongs to the best performing class of antiviral transgenes, and keeps HIV-1 host cells free of new infection by affecting the early steps of HIV-1 life cycle. AIDS patient’s own haematopoietic stem cells genetically modified ex vivo to express Chim3 (Chim3-cells) prolong their lifespan by surviving HIV-1 infection. Following re-infusion into the patient , Chim3-cells are expected to grant a life-long restoration of the immune system, required to ultimately defeat AIDS.
In-licensing opportunities
MolMed assures a constant supply of its pipeline and progress of its technology platforms through both internal activities and co-funded collaborations with major international research bodies and foundations. MolMed seeks new therapeutic product candidates and technologies thatcomplement its research and clinical development pipeline.
Licensing contact:
To discuss collaboration opportunities with MolMed, please contact:
Holger Neecke, Director Business Development & Investor Relations
holger.neecke@molmed.com
|
;)